Position in EXEL
as of Jun 30, 2026
· filed Jul 23, 2026
Position Value
$1,904
+$403 QoQ
Shares Held
35
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#165
of 180 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Steigerwald, Gordon & Koch Inc. holds $737,090 across 11 Biotechnology names. EXEL ranks #7 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LGND |
Ligand Pharmaceuticals Inc
|
1,566 | $494,996 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
185 | $115,354 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
167 | $82,953 | |
| 4 | IONS |
Ionis Pharmaceuticals Inc
|
265 | $21,011 | |
| 5 | MRNA |
Moderna, Inc.
|
150 | $10,504 | |
| 6 | VALN |
Valneva SE
|
1,250 | $6,537 | |
| 7 | EXEL |
Exelixis, Inc.
This page
|
35 | $1,904 | |
| 8 | FTRE |
Fortrea Holdings Inc.
|
100 | $1,740 |
All Filings in EXEL
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,904 | 35 | Shares | Sole | 2026-07-23 | |
| 2026-03-31 | $1,501 | 35 | Shares | Sole | 2026-04-28 | |
| 2025-12-31 | $1,534 | 35 | Shares | Sole | 2026-01-23 | |
| No filing history on record for this holder in this stock. | ||||||